What question did this study set out to answer?

Evaluate efficacy and safety of reduced-dose melphalan in multiple myeloma patients ineligible for standard dose.

March 8, 2026Annals of HematologyOpen Access

Reduced dose versus standard melphalan conditioning for autologous stem cell transplantation in multiple myeloma: a single-center retrospective study

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study shows reduced-dose melphalan improves safety in myeloma patients, suggesting it as an effective option.

Evaluate efficacy and safety of reduced-dose melphalan in multiple myeloma patients ineligible for standard dose.
Retrospective single-center study
Compared clinical outcomes between reduced-dose (140-180 mg/m2) and standard-dose (200 mg/m2) melphalan
Subgroup analyses based on age and renal function
Overall survival and progression-free survival were comparable between groups
Reduced-dose regimen showed improved safety profile with lower mucositis rates
Fewer febrile episodes and accelerated platelet engraftment observed in the reduced-dose group

Yao et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark